Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.Barrons • 02/06/26
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular AtrophyGlobeNewsWire • 02/04/26
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough StatusZacks Investment Research • 01/29/26
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment OptionsGlobeNewsWire • 01/28/26
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority ReviewGlobeNewsWire • 01/25/26
Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyGlobeNewsWire • 01/12/26
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet SyndromeBusiness Wire • 01/11/26
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in ChinaGlobeNewsWire • 01/06/26
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALSGlobeNewsWire • 12/22/25
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in CanadaBusiness Wire • 12/09/25
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug ListGlobeNewsWire • 12/08/25
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire • 12/05/25
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingGlobeNewsWire • 12/05/25
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSFGlobeNewsWire • 12/02/25
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/02/25
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual MeetingGlobeNewsWire • 12/01/25